News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Quark Pharmaceuticals Inc. Sets IPO of 5 Million Shares at $12-$14 Each
June 5, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
June 5 (Reuters) - Quark Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, on Tuesday filed with U.S. regulators to sell 5 million shares in an initial public offering at an estimated price of $12 to $14 a share.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Cardiovascular disease
Alnylam Unites With Tenaya in Potential $1B+ Pact To Find New Genetic Heart Disease Targets
March 5, 2026
·
2 min read
·
Heather McKenzie
Funding
Teva Bags $400M Backing From Blackstone To Advance Sanofi-Partnered Drug
March 4, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Sanofi Bets Up to $1.53B in Hong Kong Immuno Pact, Adding to String of Deals
March 4, 2026
·
2 min read
·
Tristan Manalac
IPO
Generate Arrives on Nasdaq Ready To Finally Show the World AI-Powered Medicines
March 2, 2026
·
3 min read
·
Annalee Armstrong
